

**Anti-Hyperglycemic and Anti-Hyperlipidemic Potentials of Methanol Leaf
Extracts of Aframomum Melegueta and Piper Guineense**

Aim: The study investigated the anti-hyperglycemic and anti-hyperlipidemic potentials of methanol extracts of Piper guineense (PG) and Aframomum melegueta (AM) leaves with a view to utilizing the plants in the treatment and management of cardiovascular disorders.

Methodology: Twenty-eight healthy albino rats were randomly divided into seven equal groups: Group I received normal saline (2 ml/kg bwt); Group II received a single dose of alloxan(150 mg/kg bwt) intraperitoneally; Group III received alloxan (150 mg/kg bwt) + glibenclamide(5 mg/kg bwt);Group IV received alloxan (150 mg/kg bwt) +PG (200 mg/kg bwt); Group V received alloxan (150 mg/kg bwt) + PG (400 mg/kg bwt); Group VI received alloxan (150 mg/kg bwt) + AM 200 (mg/kg bwt); Group VII received alloxan (150 mg/kg bwt) + AM (400 mg/kg bwt). The blood glucose level was determined before and after treatment with the extracts. The lipid profiles: (total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were estimated using the Randox diagnostic kits.

Results: The results revealed that alloxan was able to induce hyperglycemia at 150 mg/kg bwt and post-treatment with PG and AM at 200 mg/kg and 400 mg/ kg bwt were able to significantly lower the blood glucose level which was quite apparent in AM treated groups. Also, the extracts at 200 mg/kg and 400 mg/kg were able to bring a significant ($p < 0.05$) reduction in TC, TG and LDL concentrations when compared to the alloxan treated group with the highest reduction in AM treated groups.

Conclusion: These results revealed that the methanol extract of AM and PG elicited anti-hyperglycemic and anti-hyperlipidemic potentials of the extracts with the highest effect in AM treated rats.

Keywords:- Anti-hyperglycemic, Anti-hyperlipidemic, Piper guineense (PG) and Aframomum melegueta

30 1. INTRODUCTION

31 *Diabetes mellitus* (DM) is a chronic metabolic disorder and is becoming a global health concern because
32 of the increase in its prevalence. However, hyperglycemia and hyperlipidemia are some of the factors
33 indicating this metabolic syndrome [1]. Hyperglycemia is a condition in which an excessive amount of
34 [glucose](#) circulates in the [blood plasma](#). [Diabetic neuropathy](#) may be a result of long-term hyperglycemia.
35 Hyperlipidemia is characterized by abnormal elevation in plasma triglyceride, cholesterol and low density
36 lipoprotein-cholesterol (LDL-c) and very low lipoprotein - cholesterol (VLDL-c) and has also been
37 reported to be the most prevalent indicator for susceptibility to atherosclerotic heart disease [2]. Also,
38 high blood glucose levels are associated with low level of high-density lipoprotein cholesterol (HDL-c)
39 and increase of low-density lipoprotein cholesterol, thus increasing risk of coronary heart diseases.
40 Therefore, it is vital to manage both diabetes and lipid levels [3]

41 The increase in demand for cheaper therapeutics with no/minimum side effects is stimulating interest in
42 studying the use of natural products for the treatment and management of diseases [4, 5]. The medicinal
43 values of these plants are usually due to the presence of phytochemicals [6, 7, 8].

44 *Piper guineense* is a spice which belongs to the family Piperaceae commonly known as West African
45 Black Pepper. It is a climbing plant climbing up to 12m high by its adventitious rootlets. It is known with
46 different vernacular names in Nigeria which include 'Uziza' in Igbo, and 'Iyere' in Yoruba. The seeds are
47 smooth and are prolate-elliptically shaped. The seeds, leaves and sometimes the stems are used in
48 preparing soup. It imparts "heat" and a spicy pungent aroma to food [9]. The plant is utilized for a variety
49 of purposes which include human dietaries, preservative, bio-control agent as well as traditional medicine
50 [9].

51 Previous phytochemical studies of *P. guineense* seed extract revealed the presence of various substances
52 such as alkaloids, flavonoids, tannis triterpenoids, cardiac glycosides and saponins [10]. Pharmacological
53 and physiological studies of *P. guineense* extract showed depolarizing neuromuscular blocking action,
54 insecticidal properties, sexual behavioural effect and antifungal activity [11] and edema in gastrointestinal
55 tract, urinary bladder and adrenal glands and immunotoxicological effects [12].

56 *Aframomum melegueta* K. Schum belongs to the ginger family (Zingiberaceae) and it is commonly known
57 as grains of paradise or alligator pepper [13]. It is variously known locally as *ose oji* in Igbo, *ataare* in
58 Yoruba, and *cittáá* in Hausa of Nigeria. The seeds of *A. melegueta* have been variously reported to be rich
59 in carbohydrates, crude fibre, and bulk minerals [14, 5, 15] suggesting it to be of good nutritional quality,
60 and hence justifying its incorporation into diet. The report of [16, 17], NMR and GC-MS analyses of the
61 chloroform extract of the seeds and essential oils from various plant parts, respectively show the plant to

62 be rich in secondary metabolites such as modified gingerols, paradols and shogaols. These metabolites
63 account for some of peppery taste of the seeds [18]. The use of *A. melegueta* in traditional medicine in
64 treating diabetes has been age long.

65 This study investigated the anti-hyperglycemia and lipid lowering effects of the leaf extracts of AM and
66 PM.

67 **2. MATERIALS AND METHODS**

68 **2.1 Chemicals**

69 All chemicals and drugs used were obtained commercially and of analytical grade.

70 **2.1.1 Collection of plant materials**

71 The leaves of *Aframomum melegueta* and *Piper guineense* were collected in February, 2015 at Okuku,
72 Odo-Otin local government, Osun State, Nigeria. It was identified at IFE herbarium, Obafemi Awolowo
73 University, Ile- Ife.

74 The methanolic extracts of *A. melegueta* and *P. guineense* were separately prepared. The leaves were
75 dried under shade and ground into powder. Typically, the powder (200g) was macerated in 2.5 L
76 methanol (70%) at room temperature for 72h. It was then filtered using muslin cloth. The filtrates were
77 allowed to settle, decanted and filtered using filtration assembly. The filtrates were evaporated to dryness
78 using rotary evaporator. The extracts were in air tight container in a refrigerator until used.

79 **2.2 Experimental Animals**

80 Adult female and male albino rats (28) weighing between 120-150 g were obtained from the Animal
81 House, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife. The rats were housed in polyethylene
82 cages at the Animal House, Department of Biochemistry, Adeleke University, Ede and were kept under
83 standard conditions; food and water were supplied *ad libitum*. They were allowed to acclimatized for a
84 period of 14 days.

85 **2.3 Grouping and Treatment of Animals**

86 The rats were randomly assigned into seven groups of four rats in each group as follows:

87 Group I: Control (Normal saline)

88 Group II: Alloxan Treated (150 mg/kg bwt)

89 Group III: Alloxan + Gilbenclamide (5mg/kg bwt)

90 Group IV: Alloxan + PG (200 mg/kg bwt)

91 Group V: Alloxan + PG (400 mg/kg bwt)

92 Group VI: Alloxan + AM (200 mg/kg bwt)

93 Group VII: Alloxan + AM (400 mg/kg bwt)

94 The extracts and the reference drug (Gilbenclamide) were administered orally.

95 **2.4 Induction of *Diabetes* and Treatment with the Extracts**

96 The animals were allowed to fast overnight and diabetes was induced by a single intra-peritoneal injection
97 of alloxan monohydrate (150 mg/kg bwt). Increase glucose level was monitored 3 days after injection by
98 measuring the tail vein blood glucose level using glucometer. The induced rats were orally treated with
99 the extracts for 7 days.

100 **2.5 Determination of Blood Glucose Levels**

101 The level of blood glucose was determined before and after treatment with the extract and standard drug
102 by using a glucometer. The rats were subjected to fasting for 12-18 h with free access to water prior to the
103 administration of the extract and the blood glucose level was measured [19]. After the last treatment with
104 the extracts, the animals were fasted overnight and the blood samples were collected for the determination
105 of the blood glucose concentration.

106 **2.6 Sacrificing and Preparation of Blood Plasma**

107 The rats were sacrificed under mild anesthesia with ether, twenty four hours after the last treatment (oral
108 administration of extracts and drug). Blood was collected by cardiac puncture into bottles containing
109 anticoagulant (trisodium citrate, 3.8% w/v) and mixed gently. Blood plasma was prepared using standard
110 procedure as reported and modified by Bode and Oyedapo [20]. Blood sample was centrifuged on Bench
111 Centrifuge Model 90-2 (Searchtech Instrument England, UK.) at 3000 rpm for 10 min. The supernatant
112 (plasma) was collected into sterile bottles, labeled and stored in freezer for biochemical analyses.

113 **2.7 Estimation of Plasma Lipid Profiles**

114 Plasma lipid profiles: triacylglycerol (TG), total cholesterol (TC), High density lipoprotein cholesterol
115 (HDL-c), low density lipoprotein cholesterol (LDL-c), were estimated spectrophotometrically using
116 Randox assay kits.

117 **2.8 Statistical analysis**

118 The data were statistically analyzed using t-test and ANOVA with the aid of SARS software package. The
119 level of statistical significance was also compared using Duncan's multiple range test $p < 0.05$.

120 **3. RESULTS**

121 3.1 Blood Glucose Level

122 In Table 1 is the summary of the initial and final concentrations of blood glucose. After induction of
123 hyperglycemia with alloxan monohydrate, there was a significant increase ($P < 0.05$) in blood glucose level
124 of other experimental groups when compared with the normal control group. After treatment the extracts
125 at 200 mg/kg and 400 mg/kg, the blood glucose level was significantly reduced ($P < 0.05$) when compared
126 to the alloxan treated rats. This indicated the anti-hyperglycemic potentials of the extracts.

127

128 **Table 1: Effects of Methanolic Extract of PG and AM on Blood Glucose Concentration (mg/dl) of**
129 **Alloxan-induced Hyperglycemic Rats**

Treatment Group	Initial Blood Glucose (mg/dl)	Final Blood Glucose (mg/dl)	% Change
Control	80.50 ± 2.02^a	75.75 ± 1.11^e	5.90
Alloxan Treated	79.25 ± 0.85^b	199.00 ± 1.68^a	151.10
Alloxan + Gilbenclamide (5mg/kg bwt)	59.25 ± 0.48^d	95.75 ± 0.85^d	61.60
Alloxan + PG (200 mg/kg bwt)	68.25 ± 0.35^c	137.75 ± 2.66^b	101.83
Alloxan + PG (400 mg/kg bwt)	75.50 ± 1.09^b	114.50 ± 3.07^c	51.66
Alloxan + AM (200 mg/kg bwt)	79.50 ± 0.87^b	65.50 ± 1.96^d	-17.61
Alloxan + AM (400 mg/kg bwt)	74.25 ± 0.91^b	72.25 ± 1.58^d	2.69

130

131 Each value represented mean \pm SEM, n = 5 readings. Values with different superscript
132 alphabet are significantly different at $P < 0.05$.

133 3.2 Lipid Profiles

134 In Table 2 is the summary of the effect of the extracts on the plasma lipid profile of alloxan-induced
135 hyperglycemia rats. There was significant increase in the concentrations of TC, TG and LDL-c but a
136 decrease in HDL-c of the alloxan treated group when compared to the control group. However, treatment
137 with the extracts at 200 and 400 mg/kg bwt caused a significant reduction in the concentrations of TC, TG
138 and LDL-c but an increase in HDL-c.

139

140

141

142 **Table 2: The effects of methanolic extract of *Piper guineense* on lipid profile (mmol/L) of alloxan-**
 143 **induced hyperglycemic rats.**

Treatment Group	TC	TG	HDL	LDL
Control	5.99 ± 0.003 ^c	1.61 ± 0.001 ^d	4.54 ± 0.001 ^a	0.714 ± 0.008 ^c
Alloxan Treated	15.82 ± 0.019 ^a	4.89 ± 0.002 ^a	0.02 ± 0.001 ^c	13.58 ± 0.019 ^a
Alloxan + Gilbenclamide (5mg/kg bwt)	8.253 ± 0.019 ^c	1.96 ± 0.310 ^c	3.27 ± 0.019 ^c	4.09 ± 0.014 ^c
Alloxan + PG (200 mg/kg bwt)	9.448±0.0102 ^b	3.862±0.021 ^b	2.266±0.387 ^d	5.426±0.061 ^b
Alloxan + PG (400 mg/kg bwt)	7.318±0.018 ^d	2.008±0.003 ^c	4.364±0.017 ^b	5.426±0.061 ^b
Alloxan + AM (200 mg/kg bwt)	9.35 ± 0.046 ^{a c}	0.961 ± 0.032 ^{bc}	6.95 ± 0.04 ^a	1.05 ± 0.10 ^{b c}
Alloxan + AM (400 mg/kg bwt)	8.411 ± 0.062 ^{ac}	2.381 ± 0.02	7.12 ± 0.002 ^a	0.214 ± 0.07 ^d

144
 145 Values are mean ± SEM of five determinations. Values with different superscript alphabet are
 146 significantly different at P<0.05.

147 **4. Discussion**

148 The study evaluated anti-hyperglycemia and lipid-lowering effect of *A. melegueta* and *P. guineense* leaf
 149 extracts. After the administration of alloxan monohydrate, there was significant increase (p < 0.05) in the
 150 blood glucose level of the negative control group when compared to the normal control group (Table
 151 1). Elevated value of fasting blood glucose concentration observed in alloxan treated rats may be due to
 152 the toxic effect of alloxan on islet beta cells of the pancreas through its ability to induce reactive oxygen
 153 species (ROS) formation, resulting in the necrosis of the pancreas and loss of capacity of the pancreas to
 154 secrete insulin resulting to hyperglycemia [21, 22, 23].

155 Chronic exposure to hyperglycemia is the primary casual factor in the pathogenesis of diabetic
 156 complications and cause changes in vascular tissue which promote atherosclerosis [24]. Our findings is in
 157 agreement with the report of earlier studies that administration of alloxan at the dose of 250mg/kg was
 158 able to increase to elevate the fasting blood sugar levels [19, 24]. Post-treatments with 200 mg/kg and 400
 159 mg/ kg PG and AM extracts were able to significantly lower the blood glucose respectively when
 160 compared to the alloxan treated group.

161 Both extracts compared favorably with the reference drug, Gilbenclamide and the highest effect was
162 observed in *A. Melegueta* at 200 mg/kg bwt. The observed anti-hyperglycemia activity of these extracts
163 may be attributed to the presence of bioactive compounds such as flavonoids in the extract. It is well
164 documented that hypoglycemic activities of many medicinal plants are attributed to the presence of
165 phenolic compounds and flavonoids [25]. Studies also reported that flavonoids have anti-hyperglycemic
166 properties because they stimulate glucose uptake in peripheral tissues and attenuate oxidative stress
167 during diabetic conditions [26,27].

168 One of the associated metabolic disorders of diabetes is dyslipidemia which is one of the risk factors of
169 diabetes [28]. Hypercholesterolemia and hypertriglyceridemia have been reported to occur in alloxan
170 treated rats [29, 30]. The elevated values for lipid profile TC, TG, LDL-cholesterol, observed in the
171 alloxan induced diabetic rats could be partly due to increased intestinal biosynthesis of cholesterol
172 because diabetes shifted the major site of cholesterologenesis from the liver to the small intestine leading to
173 hypercholesterolemia [31]. Severe diabetes mellitus due to insulin deficiency might be accompanied with
174 a reduced LDL-receptor resulting to high concentration of serum LDL cholesterol in diabetic subjects
175 [32].

176
177 The results of the extracts treated groups revealed a significant reduction in the levels of total cholesterol,
178 triglyceride, LDL but an increase in HDL. The anti-hyperlipidemic effect was more apparent in the *A.*
179 *melegueta* treated group at 200 and 400 mg/kg bwt. This revealed anti-hyperlipidemic of the plant
180 extracts. The ability of the plant to ameliorate the lipid profile may be attributed to the presence of
181 flavonoids in the plants. The presence of flavonoids in AM and PG was earlier reported by Echo et al.
182 [33] and Fajobi et al. [34] Epidemiological studies have shown that flavonoids intake are inversely related
183 to mortality from coronary heart diseases and the incidence of heart attacks [33]

184 In conclusion, the results affirmed that the plant extracts elicited anti-hyperglycemic effect and
185 normalized the lipid profile of diabetic rats. This study showed that these spices do not just impact flavour
186 to foods, but may be sources of bioactive substances useful in the treatment and management of diabetes
187 and related disorders.

188

189

190

191

192 **REFERENCES**

- 193 1. Deguchi Y, Miyazaki K. Anti-hyperglycaemic and anti-hyperlipidemic effects of guava leaf extract
194 Nutrition and Metabolism 2010; 7: 1-10.
- 195 2. Maruthapan V, Shree K. Antihyperlipidemic potential of a polyherbal drug (Geriforte) on atherogenic
196 diet induced hyperlipidemia: A Comparison with Ayurslim. International Journal of Chemical and
197 Analytical Science 2010,3, 37-39
- 198 3.Sudasinghe HP, Peiris DC. Hypoglycemic and hypolipidemic activity of aqueous leaf extract of
199 *Passiflora suberosa* L. PeerJ, 2018; [6,e4389](https://doi.org/10.7717/peerj.4389); DOI 10.7717/peerj.4389
- 200 4. Sigh S. From exotic spice to modern drug? Cell 2007; 130: 765–768.
- 201 5. Dolui AK, Segupta R. Anti-hyperglycemic effect of different extracts of leaves of *Cajanus cajan*
202 HPLC profile of the active extracts Asian Journal of Pharmaceutical and Clinical Research 2012; 5:116–
203 119.
- 204 6. Poongothai A, Sreena, KP, Sreejith K, Uthiralingam M, Annapoorani S. Preliminary phytochemicals
205 screening of *Ficus racemosa* linn. bark. International Journal of Pharmaceuticals and Biological Sciences
206 2011; 2(2): 431-434.
- 207 7. Essien EB, Onyeike EN, Ugbeide DE, Eneke IC. Effect of aqueous extract of *Occimum basilicum*
208 leaves on some hematological and biochemical parameters of Wister albino rats. Canadian Journal on
209 Scientific and Industrial Research 2012; 3: 256-264.
- 210 8. Etim OE, Egbuna CF, Odo NM, Awah, FM. In vitro antioxidant and nitric oxide scavenging activities
211 of *Piper guineense*. Global Journal of Research in Medical Plants and Indigenous Medicine 2013; 2: 485–
212 494.
- 213 9. Martins AP, Salgueiro L, Vila R, Tomi F, Canigual S, Casanova J, Proenca DA, Cunha A, Adzet T.
214 Essential oils from four *Piper* Species. Phytochem. 1558, 49, 2019-2023.
- 215 10. Fajobi OA, Fasakin OW, Oyedapo, OO. 2017. Phytochemicals, Antioxidant Potentials, and 2, 2'-
216 diphenyl-1-picryldrazyl (DPPH) Radical Scavenging Activity of *Piper guineense* (Schumach &
217 Thonn.)Seed. African Journal of Plant Science 2017; 11: 99-104.
- 218 11. Adewoyin FB, Odaibo AB, Adewunmi CO. Mosquito repellent activity of *Piper guineense* and
219 *Xylopiya aethiopica* fruit oils. Afr. J. Trad. Compl. Alter. Med., 2006; 3(2): 79-83.
- 220 12. Daware MB, Mujumdar AM, Ghaskadbi S. Reproductive toxicity of piperine in Swiss albino
221 micePlanta Med. 2000; 66:231-236.
- 222 13. Nwaehujor CO, Eban LK Ode JO, Ejiofor CE, Igile GO. Hepatotoxicity of methanol seed extract of
223 *Aframomum melegueta* [Roscoe] K. Schum. (Grains of paradise) in Sprague-Dawley rats American
224 Journal of Biomedical Research 2014; 2: 61–66.

- 225 14. Dike, MC, Ahametula NE. Comparative study of proximate, phytochemical and mineral
226 compositions of edible plant fruits/seeds from Nigerian rainforest International Journal of Biology and
227 Chemical Sciences 2012; 6; 1905–1909.
- 228 15. Alaje DO, Owolabi KT, Olakunle TP, Oluoti OJ, Adetuberu IA. Nutritional, minerals and
229 phytochemicals composition of *Garcinia cola* [Bitter cola] and *Aframomum melegueta* (Alligator pepper)
230 IOSR Journal of Environmental Science, Toxicology And Food Technology (IOSR-JESTFT) 2014; 8:
231 86–91.
- 232 16. Owokotomo IA, Ekundayo O, Oguntuase BJ. Chemical constituents of the leaf, stem, root and seed
233 essential oils of *Aframomum melegueta* (K. Schum) from South West Nigeria. International Research
234 Journal of Pure and Applied Chemistry 2013; 4: 395–401.
- 235 17. El-Halawany AM, El-Dine RS, El-Sayed NS, Hattor I. M. Protective effect of *Aframomum melegueta*
236 phenolics against CCl₄-induced rat hepatocytes damage; role of apoptosis and pro-inflammatory cytokines
237 inhibition Science Reports 2014; 30: 5880.
- 238 18. Ajaiyeoba EO, Ekundayo O. Essential oil constituents of *Aframomum melegueta* (Roscoe) K. Schum
239 seeds (alligator pepper) from Nigeria Flavour and Fragrance Journal 2009; 14: 109–111.
- 240 19. Mojekwu TO, Yama OE, Ojokuku SA, Oyebadejo SA. Hypoglycemic effects of aqueous extract of
241 *Aframomum melegueta* leaf on alloxan-induced diabetic male albino rats Pacific Journal of Medical
242 Sciences 2011; 8: 28 – 36
- 243 20. Bode SO, Oyedapo OO. Biological activities and phytoconstituents of the lower plant *Platycerium*
244 *anglense*, Welwex Hook Journal of Medicinal Plants Research 2011; 5: 1321-1329.
- 245 21. Ohno T, Horio F, Tanaka S, Terada M, Namikawa TA. Fatty liver and hyperlipidemia in IDDM
246 (insulin dependent diabetes mellitus) of Streptozotocin treated shrews Journal of Life Science 2000;
247 66(2):125-131.
- 248 22. Lenzen S. Review: The mechanisms of alloxan- and streptozotocin-induced diabetes Diabetologia
249 2008; 51: 216–226.
- 250 23. Zafar M, Naeem-Ul H, Aaqvi A, Ahmed A. Altered liver morphology and enzymes in streptozotocin
251 induced diabetic rats International Journal of Morphology 2009; 23: 719-725.
- 252 24. [Badin JK](#), [Kole A](#), [Stivers B](#), [Progar V](#), [Pareddy A](#), [Alloosh M](#), [Sturek M](#). Diabetes Exacerbates
253 Coronary Atherosclerosis in Ossabaw Miniature Swine with Metabolic Syndrome *J. Transl. Med.* 2018;
254 16(1): 58.
- 255 25. Romano B, Pagano E, Montanaro V, Fortunato AL, Milic N, Borrelli F. Novel insights into the
256 pharmacology of flavonoids *Phytother Res.* 2013, 27(11), 1588-1596.
- 257 26. Eid HM, Martineau LC, Saleem A, Muhammad A, Vallerand D. Benhaddou-Andalousi, A.
258 Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake in muscle cells by

259 quercetin and quercetin glycosides, active principles of the antidiabetic medicinal plant *Vaccinium vitis-*
260 *idaea* Mol. Nutr. Food Res. 2010; 54(7): 991-1003.

261 27. Rauter AP, Martins A, Borges C, Mota-Filipe H, Pinto R, Sepodes B. Anti-hyperglycaemic and
262 protective effects of flavonoids on streptozotocin-induced diabetic rats *Phytother Res.* 2010; 24: S133-
263 138

264 28. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence,
265 pathophysiology, and management *Drugs* 2013; 73(4): 327-339.

266 29. Wang L, Zhang XT, Zhang HY, Yao HY, Zhang H. Effect of *Vaccinium bracteatum* Thunb. leaves
267 extract on blood glucose and plasma lipid levels in streptozotocin-induced diabetic mice *J.*
268 *Ethnopharmacol.* 2010; 130(3): 465-9.

269 30. Balamurugan R, Ignacimuthu, S. Antidiabetic and hypolipidemic effect of methanol extract of *Lippia*
270 *nodiflora* L. in streptozotocin induced diabetic rats *Asian Pac J Trop Biomed* 2011;1: S30-36.

271 31. Luka C, Tijjani H, Joel E, Ezejiofor U, Onwukike P. Hypoglycaemic properties of aqueous extracts of
272 *Anacardium occidentale*, *Moringa oleifera*, *Vernonia amygdalina* and *Helianthus annuus*: A comparative
273 study on some biochemical parameters in diabetic rats *International Journal of Pharmaceutical Science*
274 *Invention* 2013; 2: 16-22.

275 32. Swami S, Sztalryd C, Kraemer FB. Effects of streptozotocin-induced diabetes on low density
276 lipoprotein receptor expression in rat adipose tissue *Journal of Lipid Research* 1996; 37: 229-239.

277 33. Echo IA, Osuagwu AN, Agbor RB, Okaka EC, Ekanem BE. Phytochemical composition of
278 *Fromomum melegueta* and *Piper guineense* seeds *World Journal of Applied Environmental Chemistry*
279 2012; 2:17–21.

280